Peripheral blood MRD correlates with treatment benefit in CLL

Print Friendly, PDF & Email


Poster session at ASCO 2018
Photo by © ASCO/Scott Morgan 2018
Minimal residual disease (MRD) kinetics confirms the high, durable MRD-negativity with venetoclax plus rituximab in relapsed/refractory chronic lymphocytic leukemia (CLL), according to a further examination of the phase 3 MURANO study. The new results show higher concordance in MRD-negativity between bone marrow and peripheral... [Read Article]
Print Friendly, PDF & Email

Ibrutinib and venetoclax combo promising in front-line CLL

Print Friendly, PDF & Email


Attendees at ASCO 2018 Annual Meeting
Photo by © ASCO/Zach Boyden-Holmes 2018
Ibrutinib combined with venetoclax is showing promising clinical activity in the front-line treatment of patients with chronic lymphocytic leukemia (CLL), according to investigators for the CAPTIVATE study. In the first 30 patients, 77% of treatment-naïve patients had undetected minimal residual disease (MRD) in... [Read Article]
Print Friendly, PDF & Email

Older, cheaper drug formulation to remain available

Print Friendly, PDF & Email


Imbruvica (ibrutinib)
Photo courtesy of Janssen
The 140 mg capsules of Imbruvica® (ibrutinib) will remain on the market, according to Pharmacyclics LLC. Pharmacyclics (an AbbVie company) and Janssen had planned to discontinue the capsules after introducing a single-tablet formulation of Imbruvica earlier this year. However, the companies received negative feedback about the discontinuation... [Read Article]
Print Friendly, PDF & Email

Umbralisib has ‘distinct’ safety profile

Print Friendly, PDF & Email


Micrograph showing CLL
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell malignancies. Researchers said the safety profile of umbralisib “was distinct from that of other PI3Kδ inhibitors,” as it produced few immune-mediated adverse events (AEs). Umbralisib also produced an objective response... [Read Article]
Print Friendly, PDF & Email

FDA issues CRL for proposed biosimilar rituximab

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) saying the agency cannot approve Sandoz’s proposed biosimilar rituximab. Sandoz submitted the biologics licensing application for the product, known as GP2013, in September 2017. The company was seeking approval for GP2013 to treat follicular... [Read Article]
Print Friendly, PDF & Email

Radioimmunoconjugate shows activity in NHL

Print Friendly, PDF & Email


Mantle cell lymphoma
The radioimmunoconjugate 177Lu-NNV003 has demonstrated activity against non-Hodgkin lymphomas (NHLs). Experiments showed that 177Lu-NNV003 can inhibit proliferation in mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL) cell lines. 177Lu-NNV003 also exhibited an antitumor effect and prolonged survival in mouse models of MCL, DLBCL, and CLL.... [Read Article]
Print Friendly, PDF & Email

CDK inhibitor synergizes with venetoclax in CLL

Print Friendly, PDF & Email


Micrograph showing CLL
Researchers have reported “strong synergy” between the CDK2/9 inhibitor CYC065 and the Bcl-2 inhibitor venetoclax in chronic lymphocytic leukemia (CLL). Experiments indicated that CYC065 and venetoclax target parallel mechanisms that promote survival in CLL cells, working together to induce apoptosis. The drugs demonstrated synergy even in CLL samples that are... [Read Article]
Print Friendly, PDF & Email

Art education benefits blood cancer patients

Print Friendly, PDF & Email


Doctor and patient
Photo courtesy of CDC
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including those undergoing transplant. The BVAI involved an educator teaching patients art technique one-on-one for approximately 30 minutes. After a single session, patients had significant improvements in... [Read Article]
Print Friendly, PDF & Email